2010-06-08 16:21 Cobra Biologics Unitech Pharma AB announces today that it will provide Aprea AB with additional GMP manufacturing of APR-246. APR-246 is Aprea’s first candidate drug which is undergoing a Phase I clinical study for refractory hematological malignancies and prostate cancer patients in Sweden.